<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The optimal treatment of advanced <z:hpo ids='HP_0003745'>sporadic</z:hpo> Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in adults is still a matter of debate </plain></SENT>
<SENT sid="1" pm="."><plain>The salutary results of pediatric therapies did open the road for improving the adult outcome </plain></SENT>
<SENT sid="2" pm="."><plain>Between May 1988 and March 2009, 71 consecutive patients-46 adults, 25 children-affected by Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>/<z:hpo ids='HP_0001909'>leukemia</z:hpo> were treated with the same intensive pediatric protocol alternating <z:chebi fb="0" ids="28445">vincristine</z:chebi>, adriamycine and fractionated ciclophosphamide (phase A) with high dose <z:chebi fb="0" ids="44185">methotrexate</z:chebi> and high dose <z:chebi fb="0" ids="28680">cytarabine</z:chebi> (phase B) in four Italian institutions </plain></SENT>
<SENT sid="3" pm="."><plain>Eighty-nine per cent of patients were in Stage III-IV or had L3 <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Complete remissions were 67/71 (94.4%), 24/25 (96%) in children, and 43/46 (93.5%) in adults </plain></SENT>
<SENT sid="5" pm="."><plain>Toxic <z:hpo ids='HP_0011420'>deaths</z:hpo> were 3/71 (4.2%), <z:hpo ids='HP_0000001'>all</z:hpo> in adults </plain></SENT>
<SENT sid="6" pm="."><plain>There were nine relapses (one in children, eight in adults), <z:hpo ids='HP_0000001'>all</z:hpo> but one observed early </plain></SENT>
<SENT sid="7" pm="."><plain>After a median observation of 94 months (range 23-275), the Event-Free Survival rate is 92% in children and 71.7% in adults (P = 0.067) </plain></SENT>
<SENT sid="8" pm="."><plain>The 23 more recent adults received also rituximab, without differences in outcome as compared to patients who did not </plain></SENT>
<SENT sid="9" pm="."><plain>Our experience confirms that such an intensive pediatric-derived chemotherapy is feasible and improves the long-term outcome of adults with advanced Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
</text></document>